Posted by Michael Wonder on 13 May 2022
Will the FDA change how it vets drugs following the Alzheimer's debacle?
13 May 2022 - The accelerated approval of aducanumab has triggered US law makers to push for more oversight from the agency.
Nearly a year after the U.S. FDA gave the green light to a controversial drug to treat Alzheimer’s disease, law makers are attempting to amend the process that led to its approval.
